Scarica l'app Stockscreener
232.36
0.03%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$232.29
Aprire:
$233.61
Volume 24 ore:
5.42M
Relative Volume:
0.97
Capitalizzazione di mercato:
$410.48B
Reddito:
$59.64B
Utile/perdita netta:
$2.36B
Rapporto P/E:
175.33
EPS:
1.3253
Flusso di cassa netto:
$19.68B
1 W Prestazione:
+6.02%
1M Prestazione:
+1.41%
6M Prestazione:
+30.95%
1 anno Prestazione:
+36.98%
Intervallo 1D:
$230.32
$235.00
Intervallo di 1 settimana:
$216.15
$239.29
Portata 52W:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. - The Motley Fool
How higher bond yields impact AbbVie Inc. stockTrade Volume Summary & Fast Exit and Entry Trade Guides - newser.com
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer - Investing News Network
Mubadala Investment Co PJSC reports share stake in Adobe, Verizon, dissolves in RTX, AbbVie - MarketScreener
Is AbbVie Inc 4AB a good long term investmentExit Strategy Tips & Discover High-Return Stocks Before They Boom - earlytimes.in
Will AbbVie Inc. stock announce special dividendJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
AbbVie exits $1.5 billion longevity drug deal with Calico: report - Crain's Chicago Business
Is AbbVie Inc. (4AB) stock a buy before earnings resultsMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
Can AbbVie Inc. stock sustain revenue growthEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
The Fight to Save the $2.7 Billion Botox Empire - Bloomberg.com
Is AbbVie Inc. stock undervalued vs historical averages2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth - The Manila Times
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic - GlobeNewswire
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulenceJobs Report & High Accuracy Trade Alerts - newser.com
Argus Raises AbbVie's Price Target to $250 From $220 - MarketScreener
Can momentum traders help lift AbbVie Inc.IPO Watch & Consistent Growth Stock Picks - newser.com
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award - Investing News Network
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More - MSN
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+ - BioSpace
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ - PR Newswire
AbbVie exits alliance with Alphabet biotech Calico; report - pharmaphorum
Chiesi licenses AbbVie subsidiary's BBB platform - The Pharma Letter
Scotiabank Initiates AbbVie at Sector Outperform With $280 Price Target - MarketScreener
How AbbVie Inc. stock trades before earningsTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More - 24/7 Wall St.
AbbVie and Calico end groundbreaking partnership after 11 years without an approved drug - The Business Journals
Why AbbVie Inc. stock appears on watchlistsJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominancePortfolio Gains Summary & Technical Pattern Alert System - newser.com
AbbVie Shares Rise To Intraday High After Key Trading Signal - Benzinga
AbbVie Reportedly Ends Partnership With Alphabet-Backed Calico Life Sciences - Stocktwits
How reliable is AbbVie Inc. (4AB) stock dividend growthWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
AbbVie (ABBV) Ends R&D Partnership with Calico Life Sciences - GuruFocus
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance? - Yahoo Finance
AbbVie reportedly ending R&D deal with Alphabet-backed antiaging firm Calico - Seeking Alpha
AbbVie Severs Ties With Google-Backed Aging Research Biotech - MarketScreener
AbbVie cuts ties with Google-backed longevity company, lays off scientists - statnews.com
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance - Insider Monkey
How AbbVie Inc. (4AB) stock benefits from digital adoptionShort Setup & Daily Technical Forecast Reports - newser.com
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - The Manila Times
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence - AbbVie News Center
Daiwa Securities Adjusts Price Target on AbbVie to $226 From $214, Maintains Outperform Rating - MarketScreener
Fund Update: 81,625 ABBVIE (ABBV) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
AbbVie Has Many Bullish Attributes (Technical Analysis) - Seeking Alpha
Is AbbVie Inc. (4AB) stock undervalued after correctionSell Signal & Safe Entry Trade Reports - newser.com
Is AbbVie Inc. stock undervalued at current price2025 Price Action Summary & Community Driven Trade Alerts - newser.com
Ironwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess - MSN
Ironwood raises outlook for AbbVie's Linzess (IRWD:NASDAQ) - Seeking Alpha
How Analyst Views Are Shaping the Evolving Story for AbbVie - Yahoo Finance
Is AbbVie's (ABBV) Dividend Hike Amid Margin Pressures Shaping Its Investment Appeal? - Yahoo Finance
Can AbbVie Inc. stock retain market dominanceBear Alert & Fast Gain Swing Alerts - newser.com
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):